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The number of truly drug-resistant hypertensive patients 
is small if careful attention is paid to blood pressure 
measurement, lifestyle measures are instituted and treatment 
is adjusted as required. An effective drug combination for the 
treatment of resistant hypertension is an ACE inhibitor (or 
angiotensin II receptor blocker), a calcium channel blocker 
and a thiazide-like diuretic, with possibly the addition of a 
fourth drug.
Key points
• Around half of patients on antihypertensive treatment have 
blood pressures above target. However, only about one in 
three of these patients are truly treatment resistant.
• Apparent treatment resistance can be avoided by careful 
attention to blood pressure measurement, avoiding 
therapeutic inertia, careful choice of an effective and  
well-tolerated regimen, and by working together with the 
patient to implement lifestyle measures and maximise 
compliance with an antihypertensive regimen.
• Some old drugs retain their usefulness in the setting of 
resistant hypertension, and newer innovations have not 
shown unequivocal benefit.
R
esistant hypertension is generally defined as the situation that 
exists when blood pressure remains above target (usually 
140/90 mmHg, or 130/80 mmHg in individuals with diabetes) 
despite the use of at least three antihypertensive drugs in 
maximum tolerated doses. Resistant hypertension is but one of many 
reasons for treatment failure in hypertension. 
Hypertension is common and has serious consequences, and 
blood pressure is often above desired levels in patients treated for 
the condition. However, most of these inadequately treated patients 
will not be truly resistant to antihypertensive drug treatment.
The World Health Organization estimates that around one in 
three deaths globally (about 17 million in 2008) are from cardiovas-
cular disease, with the majority of these (9.4 million) being attributable 
to hypertension.1 Hypertension is held responsible for around 45% 
of deaths due to heart disease and about 51% of deaths due to stroke. 
Worldwide, about 40% of adults over 25 years of age are hypertensive, 
with the highest prevalence in low-income countries. 
In Australia, about 30% of those aged 25 years and older are 
hypertensive, a prevalence that is similar to that reported in the 
USA.2,3 A recent study of people aged over 60 years in Melbourne 
and rural Victoria showed that 52% of those on antihypertensive 
treatment had blood pressures of more than 140/90 mmHg.4 The 
most recent National Health and Nutrition Examination Survey 
(NHANES) in the USA found that 48% of hypertensive patients 
had blood pressure greater than 140/90 mmHg on treatment.3 Thus 
only half of treated patients are adequately controlled. Observational 
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data in the general population indicate that control of blood pressure 
is the key factor in reducing the excess mortality risk in this group, 
confirming results from numerous prior randomised trials that 
were more selective in their inclusion criteria.5 
This article discusses the criteria for hypertension being consid-
ered treatment resistant, the reasons this occurs and how patients 
can be treated. The flowchart on this page summarises the diagnosis 
and treatment of resistant hypertension.
Criteria for determining treatment resistance
Criteria for determining whether hypertension is resistant to treat-
ment are relative, decided by consensus and have changed over time. 
Key elements contributing to the decision are the level of blood 
pressure that should be attained and the minimum treatment that 
should be prescribed (and taken) before hypertension is declared to 
be treatment resistant. 
Initial suggestions were that blood pressure should be clearly 
above target, and a level of 150/100 mmHg was chosen arbitrarily.6 
Recent consensus is that any blood pressure above target is sufficient 
to indicate resistance. Broad agreement exists for the use of at least 
three drugs, one of which should be a diuretic, before hypertension 
can be considered to be treatment resistant.6,7 
The most detailed recommendation comes from the UK National 
Institute for Health and Care Excellence (NICE) guidelines for the 
clinical management of primary hypertension in adults.8 These 
guidelines offer explicit directions for initiation and escalation of 
treatment, with the recommendation that a three-drug regimen 
includes an ACE inhibitor or angiotensin II receptor blocker, a 
calcium channel blocker and a thiazide-like diuretic.
Reasons for apparent antihypertensive drug resistance
Incorrect blood pressure measurement
The technique and method of measuring blood pressure is important 
to ensure that blood pressure is truly above target. 
Measuring blood pressure in obese subjects can be quite a chal-
lenge.9 The use of a cuff that is too small in obese patients results in 
overestimation of blood pressure.10 Occasionally, it may not be 
physically possible to have an appropriately wide cuff in a short, 
obese arm; in such a situation, the use of a cuff around the forearm 
can provide a solution.10 
Typically, office blood pressure has been utilised to define 
 treatment resistance. The recognition of ‘white-coat’ hypertension 
in other contexts prompted the use of ambulatory blood pressure 
to evaluate resistant hypertension. One study found that patients 
with elevated blood pressure in the office but not on ambulatory 
measurements (i.e. white-coat hypertension) had similar rates of 
cardiovascular events to those whose blood pressure had fallen to 
acceptable levels on treatment.11 Those who had elevated blood 
pressure on ambulatory measurements as well as office measurements 
(true resistant hypertension) had more cardiovascular events than 
those with acceptable blood pressure on treatment, whereas those 
with elevated ambulatory but adequate office pressure (masked 
Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin II 
receptor blocker; BP = blood pressure.
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 hypertension) had an intermediate rate of cardiovascular events.11 
Other studies have reported similar findings.12,13 Thus a strong case 
can be made for measuring ambulatory pressure when resistant 
hypertension is suspected. 
If ambulatory blood pressure is unavailable, home blood pressure 
measurement is a reasonable substitute. It should be noted that the 
ambulatory equivalent of a clinic blood pressure of above 
140/90 mmHg is a daytime ambulatory blood pressure of above 
135/85 mmHg.14 Using a cut-off level of 140/90 mmHg on ambulatory 
measurements will misclassify patients as being adequately treated 
when they are not.
Treatment inertia
Agreement about the minimum treatment requirement before 
hypertension is declared resistant discloses a large group of patients 
who are neither controlled nor on a three-drug regimen. For the 
most part, these circumstances indicate treatment inertia, a problem 
to which both patients and doctors contribute. A recent study con-
ducted in Melbourne and rural Victoria found that just over half of 
treated hypertensive subjects had blood pressures of 140/90 mmHg 
or higher and nearly 80% of these were on one or two antihypertensive 
drugs.4 Of even greater concern, only 20% of patients whose blood 
pressure on treatment was 160/100 mmHg or higher were on three 
drugs. Uncontrolled hypertension often has more to do with treat-
ment inertia than with treatment resistance.
Drug side effects and noncompliance
At times patients complain of intolerable drug side effects, making 
it difficult to find a regimen that is both effective and well tolerated. 
If many medications elicit symptoms suggestive of hypotension 
it would be important to consider and exclude ‘white-coat 
resistance’. 
Occasionally, it may have to be accepted that, at least from the 
patient’s perspective, the cost in side effects is not worth the gain. 
The patient might decide that daily symptoms incurred in the treat-
ment of an asymptomatic condition are unacceptable when there is 
no certain benefit, only a reduction in the risk of a possible future 
cardiovascular event.
Another reason for apparent drug resistance is nonadherence to 
prescribed treatment. Failure to take medications as prescribed is 
common across a wide range of illnesses.15 Compliance may peak 
around the time of an outpatient appointment, making it more difficult 
to detect noncompliance.16 Dosing frequency and regimen complexity 
contribute to limited persistence with prescribed treatment.17 
A range of solutions make good sense: for example, better 
 communication between doctor and patient, patient education and 
involving the patient in their own management (such as home blood 
pressure measurement).15,18 However, empirical evidence of efficacy 
of these approaches is limited. A recent systematic review recommends 
the simplification of dosing regimens to improve compliance and 
suggests that education alone is not particularly effective.19 
What characterises the treatment-resistant patient?
Excluding hypertensive patients with ‘white-coat resistance’, thera-
peutic inertia and noncompliance leaves a core of patients whose 
blood pressure is genuinely resistant to drug treatment. The size of 
the problem is difficult to estimate. 
One study determined the incidence of resistance in 205,750 
patients with incident hypertension and found that 1.9% developed 
resistant hypertension within a median of 1.5 years from initial 
treatment (0.7 cases per 100 person-years of follow up).20 Prevalence 
has been estimated from population studies where treatment details 
are difficult to ascertain and from large clinical trials where partic-
ipants may not be representative of the wider population. A recent 
review pooled data from several studies (including epidemiological 
studies and controlled trials) to report a prevalence of resistant 
hypertension of 14.8% in treated hypertensive patients.21 
Those with resistant hypertension are more likely to smoke and 
drink alcohol to excess; more likely to be older, male and obese; and 
more likely to have diabetes, target organ damage and cardiovascular 
disease or a high predicted cardiovascular risk.22-25 Adverse cardio-
vascular outcomes and mortality are increased in patients with resistant 
hypertension, providing a strong imperative to gain control of blood 
pressure.20,21,26,27  
Secondary hypertension, including drug-induced 
hypertension
Secondary hypertension is more common in patients with resistant 
hypertension than in unselected patients.7 The causes of secondary 
hypertension that should be considered are listed in Box 1.7,28
Resistant hypertension has a strong association with sleep apnoea, 
but the response to treatment is variable and meta-analyses report a 
modest average fall in blood pressure with CPAP.7,28,29 Hyperaldo-
steronism and renal parenchymal disease are also common in patients 
with resistant hypertension.7 
Other important causes of secondary hypertension are the drugs 
that raise blood pressure or interfere with the efficacy of antihyper-
tensive drugs (Box 2). Common examples are NSAIDs, sympatho-
mimetics (nasal decongestants, appetite suppressants), steroids (oral 
contraceptives, glucocorticoids) and related agents (e.g. liquorice, 
which inhibits 11beta-hydroxysteroid dehydrogenase allowing cortisol 
to activate mineralocorticoid receptors). Several of the new anticancer 
1. Causes of secondary hypertension




• Renal parenchymal disease
• Renal artery stenosis
• Phaeochromocytoma
• Drugs or chemicals (see Box 2)
RESISTANT HYPERTENSION CONTINUED
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drugs (and especially the antivascular endothelial growth factor 
therapies) can affect blood pressure.30 
What can be done for treatment-resistant patients?
Lifestyle adjustment
Obesity, moderate alcohol consumption and excessive intake of salt 
all increase blood pressure. Strategies to lose weight and reduce the 
intakes of alcohol and salt help lower blood pressure. The challenge 
for the patient and the treating physician has been the implementation 
and maintenance of lifestyle change. Salt reduction appears to be 
particularly effective in the setting of treatment resistance.31
Pharmacological treatment
Optimising the antihypertensive regimen is important for patients with 
resistant hypertension. The use of certain drugs in combination is more 
effective than combinations of other drugs.32,33 An ACE inhibitor (or 
angiotensin II receptor blocker), a calcium channel blocker and a diuretic, 
as recommended by NICE, is an effective combination.8 Combinations 
of an ACE inhibitor and an angiotensin II receptor blocker (dual renin–
angiotensin–aldosterone blockade) or an ACE inhibitor and a beta 
blocker are less than additive in lowering blood pressure.
The addition of a fourth drug is reasonable once the best three-drug 
combination has been established for the individual patient. There is 
a paucity of evidence for effective add-on medications in this setting. 
After early promising results, the endothelin antagonist darusentan 
has been shown to be relatively ineffective at lowering ambulatory 
blood pressure.34 The only drugs for which there is evidence for efficacy 
from randomised controlled trials in the setting of resistant hyper-
tension are spironolactone and minoxidil.35-37 Minoxidil is effective 
but difficult to use: its use is regularly accompanied by fluid retention 
and tachycardia that may need to be combated by other drugs (diuretics 
and beta blockade), and it can cause hirsutism.37 
Another approach that has been shown to be useful in a randomised 
trial is sequential nephron blockade (the concurrent use of diuretics 
that act at different sites of the renal tubule).38 The obvious hazard with 
this approach is volume depletion and renal impairment. 
Several other drugs can be used to lower blood pressure but have 
not been trialled in the setting of resistant hypertension. These 
include vasodilators such as hydralazine, alpha adrenergic receptor 
antagonists and centrally acting antihypertensive drugs.
Device-based procedures 
Two device-based procedures have been used in recent years to treat 
patients with resistant hypertension: renal denervation and carot-
id-baroreceptor nerve stimulation. At present, neither procedure 
can be unequivocally recommended. Deployment should be 
 performed in specialised units, preferably in clinical trials that will 
help define the place of these new treatments. 
Renal denervation 
Renal denervation had been rapidly adopted after unrandomised 
proof-of-principle and randomised but unblinded studies showed 
very substantial efficacy: a fall of 27/17 mmHg at 12 months in the 
former study and 32/12 mmHg at six months in the latter.39,40 Unfor-
tunately, the keenly awaited double-blind, sham-controlled study 
(Symplicity-3) has recently reported disappointing results: a 
2.39 mmHg between group difference for office blood pressure and 
a 1.96 mmHg between group difference in 24-hour ambulatory 
systolic blood pressure.41 Whether the apparent difference in efficacy 
in these three studies is a result of more rigorous evaluation of efficacy 
in Symplicity-3, differences in the patient population enrolled in the 
three studies or the experience of the operators is hotly debated. 
Carotid-baroreflex activation
Baroreflex activation is more difficult to deploy than renal denervation 
and is not yet generally available. Initial promising results in a non-
randomised study42 were followed by less impressive results in a 
randomised blinded study (the device was implanted but not switched 
on in the control group). In this study, baroreflex activation resulted 
in no significant difference between treated subjects and controls 
(16 ± 29 mmHg and 9 ± 29 mmHg, respectively).43
Summary
If careful attention is paid to measuring blood pressure, instituting 
lifestyle measures and adjusting treatment as required, the number 
of truly drug-resistant hypertensive patients is small. A second look 
for underlying causes of hypertension is warranted in this group, 
including in particular the possibility that concurrent treatment is 
contributing to elevated blood pressure. Some old drugs retain their 
usefulness in the setting of resistant hypertension, and newer inno-
vations have not shown unequivocal benefit.  CT
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2. Hypertension induced by drugs or chemicals
• Sympathomimetic agents (weight-loss pills, decongestants, 
amphetamine and amphetamine-like substances, cocaine, 
herbal agents such as ephedra [ma huang])
• Steroids and related substances 
– oral contraceptive pills and exogenous oestrogen
– exogenous glucocorticoids and mineralocorticoids
– liquorice (allows cortisol to activate mineralocorticoid receptors)
• Antidepressants
• Alcohol
• Immunosuppressants (especially cyclosporin)
• Erythropoietin
• Anticancer drugs (especially anti-VEGF drugs)
Abbreviation: VEGF = vascular endothelial growth factor.
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